ACTEMRA® (tocilizumab) is a prescription treatment for patients 2 years and older with systemic juvenile idiopathic arthritis (SJIA). It is thought to block the IL-6 receptor, a key messenger that is believed to cause the immune system to attack the healthy cells which can contribute to the signs and symptoms of SJIA.
ACTEMRA is given by IV infusion or SC injection. For IV: children <30 kg receive 12 mg/kg every 2 weeks, and ≥30 kg receive 8 mg/kg every 2 weeks. For SC: <30 kg is 162 mg every 2 weeks; ≥30 kg is 162 mg weekly.
Common adverse effects include sinus infections, headache, higher blood pressure, and injection-site reactions. Serious side effects include serious infections, gastrointestinal perforation, hematologic events, hepatotoxicity, and hypersensitivity. Monitoring includes periodic CBC, liver enzymes, lipids; and screening for latent TB and hepatitis before starting. Seek medical attention for fever, persistent cough, abdominal pain, or allergic signs. Do not take ACTEMRA if you are allergic to tocilizumab, or any of the ingredients in ACTEMRA.